Table 2 The results of the univariate analyses and Cox multivariate analyses of factors predicting the PFS (n = 52)
Univariate | Multivariate | |||
|---|---|---|---|---|
Variables | HR (95% CI) | p Value* | HR (95% CI) | p Value* |
Age | ||||
(< 70 years vs. ≥70 years) | 1.084 (0.57–2.06) | 0.804 | ||
Sex | ||||
(Male vs. Female) | 1.281 (0.92–1.76) | 0.137 | ||
Prior nephrectomy | ||||
(yes vs. no) | 2.341 (1.01–5.04) | 0.046 | ||
ECOG PS | ||||
(0 vs. ≥1) | 2.072 (1.09–3.94) | 0.026 | ||
Treatment line of nivolumab | ||||
(2 vs. ≥3) | 1.454 (0.77–2.75) | 0.251 | ||
IMDC risk classification | ||||
(Favorable, Intermediate vs. Poor) | 2.331 (1.02–5.33) | 0.045 | ||
Number of Metastatic Organ site | ||||
(1,2 vs. ≥3) | 1.023 (0.55–1.92) | 0.944 | ||
CRP at baseline | ||||
(< 10 mg/L vs. ≥10 mg/L) | 1.001 (0.53–1.89) | 0.997 | ||
NLR at baseline | ||||
(< 3 vs. ≥3) | 1.147 (0.60–2.12) | 0.676 | ||
NLR at 4 weeks | ||||
(< 3 vs. ≥3) | 2.340 (1.19–4.59) | 0.013 | 2.340 (1.19–4.59) | 0.013 |